(9-methoxy-3-methyl-2,4,4a,5,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl) benzoate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (9-methoxy-3-methyl-2,4,4a,5,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl) benzoate
• 化学式: C₂₅H₂₅NO₄
• 分子量: 403.5
• InChiKey: VPMRSLWWUXNYRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF
  申请人：Mickle Travis

  公开号：US20110002990A1

  公开（公告）日：2011-01-06

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供了包含芳基羧酸与羟考酮（吗啡酮-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）化学共轭形成的新型羟考酮前药/组合物，包括苯甲酸酯和杂环芳基羧酸，具有降低滥用羟考酮潜力的特性。该技术还提供了治疗患者的方法、制药工具包和合成本技术共轭物的方法。
• [EN] IMMEDIATE-RELEASE ABUSE DETERRENT COMPOSITIONS OR MEDICAMENTS FOR TREATING PAIN, ADD, ADHD AND OTHER SYNDROMES OR DISORDERS<br/>[FR] COMPOSITIONS ANTI-ABUS À LIBÉRATION IMMÉDIATE OU MÉDICAMENTS DESTINÉS AU TRAITEMENT DE LA DOULEUR, DU DCA, DU TDAH, ET D'AUTRES SYNDROMES OU TROUBLES
  申请人：KEMPHARM INC

  公开号：WO2018071879A1

  公开（公告）日：2018-04-19

  The presently described technology provides one or more compositions, preferably one or more immediate-release profile compositions, comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5- alpha-epoxy-3-methoxy-17-methyl), or chemically conjugated to hydromorphone (4,5,α-epoxy-3-hydroxy-17-methyl morphinan-6-one), in combination with at least one gel forming polymer; at least one disintegrant; and at least one surfactant to form novel compositions which have a decreased potential for abuse. The hydrocodone conjugate can also be combined with an analgesic, such as acetaminophen, to form a combinatorial composition that includes at least one gel forming polymer; at least one disintegrant; and at least one surfactant. The present technology also provides pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供了一种或多种组合物，最好是一种或多种立即释放剖面组合物，其中含有与羟考酮（吗啡-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）或与羟吗啡（4,5,α-环氧-3-羟基-17-甲基吗啡-6-酮）化学结合的芳基羧酸，结合至少一种凝胶形成聚合物；至少一种崩解剂；和至少一种表面活性剂，以形成具有减少滥用潜力的新型组合物。羟考酮结合物还可以与镇痛剂（如对乙酰氨基酚）结合，形成包括至少一种凝胶形成聚合物；至少一种崩解剂；和至少一种表面活性剂的组合物。该技术还提供了药物配套组和合成本技术结合物的方法。
• Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof
  申请人：KemPharm, Inc.

  公开号：US20150335759A1

  公开（公告）日：2015-11-26

  The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.

  目前描述的技术提供了治疗患有中度至严重疼痛、麻醉药或阿片类药物滥用或戒断症状的患者的方法。目前描述的方法是通过向患者施用包含对乙酰氨基酚和苯甲酸盐羟考酮盐酸盐的药物有效量的组合物来实施的。与未结合的羟考酮相比，该组合物具有减少的副作用。
• Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
  申请人：Mickle Travis

  公开号：US20120142719A1

  公开（公告）日：2012-06-07

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供了一种组合物，其中包括芳基羧酸与氢可酮（吗啡酮-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）化学共轭形成的新型氢可酮前药/组合物，包括苯甲酸酯和杂环羧酸，具有降低氢可酮滥用潜力的特点。该技术还提供了治疗患者的方法、药物工具包以及合成该技术共轭物的方法。
• Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Uses Thereof
  申请人：KemPharm, Inc.

  公开号：US20150065536A1

  公开（公告）日：2015-03-05

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前所描述的技术提供了化学共轭的芳基羧酸与氢可酮（吗啡酮，4,5-α-环氧-3-甲氧基-17-甲基）形成的新型前药/氢可酮组合物，包括苯甲酸酯和杂环羧酸，其具有降低滥用氢可酮的潜力。本技术还提供了治疗患者的方法、制药套件和合成本技术共轭物的方法。